Stock NSIS B NOVONESIS A/S
Add to a list
To use this feature you must be a member
Log inSign up

Financials Novonesis A/S

Equities

NSIS B

DK0060336014

Specialty Chemicals

Market Closed - Nasdaq Copenhagen
Other stock markets
 10:59:38 2024-05-31 am EDT 		5-day change 1st Jan Change
408.6 DKK -0.90% Intraday chart for Novonesis A/S -3.65% +10.11%
May. 10 NOVONESIS : Key segments outperform in average Q1 24 showing Alphavalue
May. 03 Transcript : Novozymes A/S, Q1 2024 Sales/ Trading Statement Call, May 03, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 91,696 97,943 148,795 97,304 102,816 189,842 - -
Enterprise Value (EV) 1 95,745 101,814 154,020 103,111 109,433 204,578 202,241 200,874
P/E ratio 29.6 x 34.9 x 47.8 x 26.7 x 34.1 x 48.6 x 33.8 x 29.7 x
Yield 1.61% 1.5% 1.02% 1.71% 1.13% 1.36% 1.64% 1.77%
Capitalization / Revenue 6.38 x 6.99 x 9.95 x 5.54 x 5.74 x 6.47 x 6.06 x 5.67 x
EV / Revenue 6.66 x 7.27 x 10.3 x 5.87 x 6.11 x 6.98 x 6.46 x 6 x
EV / EBITDA 18.1 x 20.7 x 28.4 x 17.1 x 20.4 x 20.2 x 17.7 x 16 x
EV / FCF 36.3 x 29.8 x 54.6 x 92.4 x 52.2 x 52.6 x 35.6 x 30 x
FCF Yield 2.75% 3.35% 1.83% 1.08% 1.92% 1.9% 2.81% 3.33%
Price to Book 8.27 x 8.87 x 12.8 x 7.15 x 7.38 x 2.29 x 2.23 x 2.18 x
Nbr of stocks (in thousands) 281,276 280,237 276,983 276,511 277,058 464,616 - -
Reference price 2 326.0 349.5 537.2 351.9 371.1 408.6 408.6 408.6
Announcement Date 1/23/20 2/2/21 2/1/22 1/26/23 2/1/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 14,374 14,012 14,951 17,553 17,899 29,327 31,329 33,484
EBITDA 1 5,292 4,918 5,423 6,046 5,365 10,142 11,445 12,525
EBIT 1 4,039 3,652 4,007 4,629 4,552 7,973 9,052 9,897
Operating Margin 28.1% 26.06% 26.8% 26.37% 25.43% 27.19% 28.89% 29.56%
Earnings before Tax (EBT) 1 3,799 3,521 3,924 4,556 3,909 5,185 6,933 8,071
Net income 1 3,154 2,825 3,146 3,676 3,024 3,625 5,268 6,141
Net margin 21.94% 20.16% 21.04% 20.94% 16.89% 12.36% 16.82% 18.34%
EPS 2 11.01 10.02 11.23 13.19 10.88 8.408 12.07 13.76
Free Cash Flow 1 2,635 3,415 2,822 1,116 2,096 3,889 5,679 6,693
FCF margin 18.33% 24.37% 18.87% 6.36% 11.71% 13.26% 18.13% 19.99%
FCF Conversion (EBITDA) 49.79% 69.44% 52.04% 18.46% 39.07% 38.35% 49.62% 53.44%
FCF Conversion (Net income) 83.54% 120.88% 89.7% 30.36% 69.31% 107.3% 107.8% 108.99%
Dividend per Share 2 5.250 5.250 5.500 6.000 4.200 5.540 6.700 7.251
Announcement Date 1/23/20 2/2/21 2/1/22 1/26/23 2/1/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1 2025 S1 2025 S2
Net sales 1 3,761 3,834 4,371 4,286 4,367 4,529 4,623 4,217 4,456 4,603 7,243 14,428 7,385 7,407 14,954 - 15,517 16,083
EBITDA 1 1,448 1,150 1,503 1,487 1,664 1,392 1,491 1,200 1,516 1,320 2,529 5,046 2,674 2,547 5,221 - - -
EBIT 1 1,095 805 1,142 1,110 1,287 1,059 1,200 1,011 1,184 1,157 1,940 3,912 2,089 1,962 4,117 - 4,547 4,793
Operating Margin 29.11% 21% 26.13% 25.9% 29.47% 23.38% 25.96% 23.97% 26.57% 25.14% 26.78% 27.11% 28.28% 26.49% 27.53% - 29.3% 29.8%
Earnings before Tax (EBT) 1,054 771 1,076 1,047 1,388 1,045 1,040 798 1,148 923 - 2,208 - - 2,007 - - -
Net income 1 843 625 832 817 1,153 883 784 614 936 698 692.1 1,537 800.5 800.5 1,395 - - -
Net margin 22.41% 16.3% 19.03% 19.06% 26.4% 19.5% 16.96% 14.56% 21.01% 15.16% 9.56% 10.65% 10.84% 10.81% 9.33% - - -
EPS 2 3.010 2.240 2.980 2.900 4.140 3.180 2.820 2.180 3.370 2.510 1.478 4.402 1.709 1.709 4.440 - 7.165 7.538
Dividend per Share 2 - 5.500 - - - 6.000 - - - 4.200 - - - 5.580 - - - -
Announcement Date 10/26/21 2/1/22 4/26/22 8/11/22 11/3/22 1/26/23 4/26/23 8/9/23 10/26/23 2/1/24 - - - - - - - -
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 4,049 3,871 5,225 5,807 6,617 14,736 12,399 11,032
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.7651 x 0.7871 x 0.9635 x 0.9605 x 1.233 x 1.453 x 1.083 x 0.8808 x
Free Cash Flow 1 2,635 3,415 2,822 1,116 2,096 3,889 5,679 6,693
ROE (net income / shareholders' equity) 27.5% 24.9% 27.3% 28.6% 21.7% 6.43% 6.8% 7.74%
ROA (Net income/ Total Assets) 15.7% 13.8% 13.9% 13.9% 10.7% 5.19% 6.53% 7.42%
Assets 1 20,067 20,474 22,638 26,375 28,187 69,809 80,675 82,734
Book Value Per Share 2 39.40 39.40 41.90 49.20 50.30 179.0 183.0 188.0
Cash Flow per Share 2 11.20 15.40 14.50 14.40 14.90 15.70 18.80 21.00
Capex 1 997 940 1,240 2,890 2,056 3,074 3,220 3,257
Capex / Sales 6.94% 6.71% 8.29% 16.46% 11.49% 10.48% 10.28% 9.73%
Announcement Date 1/23/20 2/2/21 2/1/22 1/26/23 2/1/24 - - -
1DKK in Million2DKK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Novonesis A/S

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
408.6 DKK
Average target price
437.4 DKK
Spread / Average Target
+7.04%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Industrial Biotechnology Chemicals

1st Jan change Capi.
NOVONESIS A/S Stock Novonesis A/S
+10.11% 27.6B
CATHAY BIOTECH INC. Stock Cathay Biotech Inc.
-11.53% 3.9B
BORREGAARD ASA Stock Borregaard ASA
+12.25% 1.83B
PUYANG HUICHENG ELECTRONIC MATERIAL CO., LTD. Stock Puyang Huicheng Electronic Material Co., Ltd.
-4.30% 683M
HENAN JINDAN LACTIC ACID TECHNOLOGY CO.,LTD. Stock Henan Jindan Lactic Acid Technology Co.,Ltd.
-21.50% 421M
BIO-ON S.P.A. Stock Bio-on S.p.A.
-81.65% 216M
CHEMCON SPECIALITY CHEMICALS LIMITED Stock Chemcon Speciality Chemicals Limited
-18.97% 104M
I-TECH AB Stock I-Tech AB
-6.88% 58.11M
Industrial Biotechnology Chemicals
  1. Stock Market
  2. Equities
  3. NSIS B Stock
  4. Financials Novonesis A/S